Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Acronyms ORKAMBI
- 11 Oct 2019 Results (n=845) published in the American Journal of Respiratory and Critical Care Medicine.
- 18 May 2018 Planned End Date changed from 15 Jan 2020 to 30 Jun 2018.
- 18 May 2018 Planned primary completion date changed from 30 Dec 2018 to 30 Jun 2018.